靶向血管内皮生长因子/血管内皮生长因子受体-2的血管生成抑制剂

被引：20

作者：

王秀云 ^{[1
]}

王锦政 ^{[1
]}

张娟 ^{[1
]}

冯亚宁 ^{[2
]}

王旻 ^{[1
]}

机构：

[1] 中国药科大学生命科学与技术学院

[2] 华东医药公司

来源：

药学进展 | 2013年 / 37卷 / 01期

关键词：

血管内皮生长因子; 血管内皮生长因子受体-2; 血管生成抑制剂; 抗肿瘤;

D O I：

暂无

中图分类号：

R96 [药理学];

学科分类号：

100706 [药理学];

摘要：

血管内皮生长因子(VEGF)及血管内皮生长因子受体-2(VEGFR-2)是调节血管生成、内皮细胞增殖和迁移等的关键调控因子。通过阻断VEGF与VEGFR-2的结合可抑制新生血管形成,而新生血管的形成是肿瘤生长和转移的基础。介绍VEGF/VEGFR-2在血管形成中的作用,以及具有抗肿瘤作用的靶向VEGF/VEGFR-2的血管生成抑制剂的研究近况。

引用

页码：8 / 16

页数：9

共 7 条

[1]

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab [J].

Papadopoulos, Nicholas ;

Martin, Joel ;

Ruan, Qin ;

Rafique, Ashique ;

Rosconi, Michael P. ;

Shi, Ergang ;

Pyles, Erica A. ;

Yancopoulos, George D. ;

Stahl, Neil ;

Wiegand, Stanley J. .

ANGIOGENESIS, 2012, 15 (02) :171-185

[2]

VEGFR-2 expression in human melanoma: revised assessment [J].

Molhoek, Kerrington R. ;

Erdag, Gulsun ;

Rasamny, Jk ;

Murphy, Cheryl ;

Deacon, Donna ;

Patterson, James W. ;

Slingluff, Craig L., Jr. ;

Brautigan, David L. .

INTERNATIONAL JOURNAL OF CANCER, 2011, 129 (12) :2807-2815

[3]

VEGF and angiopoietin signaling in tumor angiogenesis and metastasis [J].

Saharinen, Pipsa ;

Eklund, Lauri ;

Pulkki, Kristina ;

Bono, Petri ;

Alitalo, Kari .

TRENDS IN MOLECULAR MEDICINE, 2011, 17 (07) :347-362

[4]

Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition [J].

Holmes, Katherine ;

Roberts, Owain Ll ;

Thomas, Angharad M. ;

Cross, Michael J. .

CELLULAR SIGNALLING, 2007, 19 (10) :2003-2012

[5]

Protein kinase C-γ activation in the early streptozotocin diabetic rat lens [J].

Lin, Dingbo ;

Harris, Richie ;

Stutzman, Rachael ;

Zampighi, Guido A. ;

Davidson, Harriett ;

Takemoto, Dolores J. .

CURRENT EYE RESEARCH, 2007, 32 (06) :523-532

[6]

VEGF/VEGFR signalling as a target for inhibiting angiogenesis [J].

Kiselyov, Alex ;

Balakin, Konstantin V. ;

Tkachenko, Sergey E. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (01) :83-107

[7]

A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model.[J].Wei Zhang;Sophia Ran;M. Sambade;Xianming Huang;Philip E. Thorpe.Angiogenesis.2002, 1

← 1 →